Visceral Leishmaniasis Clinical Management in Endemic Districts of India, Nepal, and Bangladesh

Table 2

VL management practices: observation of doctor patient consultations.

	India		Nepal		Bangladesh		Overall
	2009	2010	2009	2010	2009	2010	2009	2010
No. of doctor-patient consultations observed: 1st visit	(𝑛=23)	(𝑛=23)	(𝑛=3)	(𝑛=12)	(𝑛=5)	(𝑛=18)	(𝑛=31)	(𝑛=53)
Follow-up visit	(𝑛=13)	(𝑛=0)	(𝑛=0)	(𝑛=0)	(𝑛=17)	(𝑛=20)	(𝑛=30)	(𝑛=20)
(i) Doctor asked patient for family h/o VL at 1st visit	13/23; (57%)	11/23; (48%)	3/3; (100%)	9/12; (75%)	5/5; (100%)	18/18; (100%)	21/31; (68%)	38/53; (72%)
(ii) Doctor asked about pregnancy at 1st visit of women of reproductive age	5/7; (71%)	6/6; (100%)	—	1/6; (17%)	1/1; (100%)	—	6/8; (75%)	7/12; (58%)
(iii) Doctor advised drug dose based on patient’s weight at 1st visit	22/23; (96%)	23/23; (100%)	3/3; (100%)	10/12; (83%)	5/5; (100%)	18/18; (100%)	30/31; (97%)	51/53; (96%)
(iv) Temperature of patient was measured	23/36; (64%)	23/23; (100%)	3/3; (100%)	5/12; (42%)	5/22; (23%)	18/38; (47%)	31/61; (51%)	46/73; (63%)
(v) Doctor examined patient for spleen enlargement	23/36; (64%)	23/23; (100%)	3/3; (100%)	12/12; (100%)	5/22; (23%)	18/38; (47%)	31/61; (51%)	53/73; (73%)
(vi) Doctor advised blood tests for patient	21/36; (58%)	20/23; (87%)	3/3; (100%)	5/12; (42%)	3/22; (14%)	12/38; (32%)	27/61; (44%)	37/73; (51%)
(vii) On FU visit, doctor asked patient for side effects	13/13; (100%)	—	—	—	1/17; (6%)	19/20; (95%)	14/30; (47%)	19/20; (95%)